Answer
Fatigue, dizziness and somnolence reported during treatment with the components of Emtricitabine/Rilpivirine/Tenofovir Alafenamide Gilead should be considered when assessing driving or machinery use; the medicine may have a minor influence on these abilities.
Sources for this answer
- Emtricitabine/Rilpivirine/Tenofovir Alafenamide Gilead 200 mg/25 mg/25 mg film-coated tabletsGilead Sciences Ltd · emc · SmPC §4.7 Effects on ability to drive and use machines · Version 24Document updated
Sources checked